Close Menu

NEW YORK – Oncocyte announced on Friday it has reached definitive agreements with institutional investors that will purchase about $10.7 million of the company's common shares in a registered offering.

The investors, which include Blackcrane Capital, will purchase the shares at an at-the-market price of $2.27 per share, the closing price of Oncocyte's stock immediately preceding the offering. Oncocyte is selling about 4.7 million shares in the offering, which is expected to close next week.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.